What is Alzheimer's Disease? Causes and Treatment in Manhattan, NYC

Alzheimer’s Disease

Alzheimer's Disease: Symptoms, Stages, Causes & Integrative Treatment in NYC

Alzheimer’s disease is a progressive neurodegenerative disorder in which the abnormal accumulation of amyloid-beta plaques and tau tangles destroys neural connections — beginning in the hippocampus and ultimately affecting nearly every region of the brain. For the more than 6.9 million Americans living with Alzheimer’s, the lived experience is one of slowly losing the memories, relationships, and independence that define a life — while families search desperately for answers beyond symptom management.

6.9M

Americans living with Alzheimer’s (2024)

15–20 yrs

Pathology builds before first symptoms

2/3

Of patients are women

35%

Of cases linked to modifiable risk factors

Medically reviewed by Dr. Rashmi Gulati, MD — Medical Director, Patients Medical.

Board-certified integrative medicine physician.

Clinical Definition

Alzheimer’s disease is a progressive, irreversible neurodegenerative disorder defined by the pathological accumulation of extracellular amyloid-beta plaques and intraneuronal hyperphosphorylated tau neurofibrillary tangles, leading to synaptic dysfunction, cholinergic deficit, widespread neuronal death, and the progressive loss of memory, cognition, and functional independence. It is the sixth leading cause of death in the United States and the most common cause of dementia, affecting an estimated 6.9 million Americans over age 65 in 2024. Functional medicine approaches the condition by identifying and correcting its modifiable upstream drivers — including insulin resistance, systemic inflammation, hormonal decline, heavy metal burden, and mitochondrial dysfunction — rather than targeting symptoms alone.

Key Symptoms

Progressive short-term memory loss
Word-finding difficulty (aphasia)
Disorientation to time and place
Impaired executive function
Personality and behavioural changes
Sleep disruption and sundowning

Primary Causes

Amyloid-beta plaque accumulation
Insulin resistance (Type 3 diabetes)
Chronic neuroinflammation
APOE4 genetic susceptibility
Heavy metal toxicity (Hg, Pb, Al)
Mitochondrial energy failure

Treatment Approach

Bredesen (ReCODE) Protocol
Ketogenic / MIND diet therapy
NAD+ IV Infusion
Hormone optimisation
Heavy metal chelation
Targeted nutraceutical protocol

What Is Alzheimer's Disease?

Alzheimer’s disease is the most common cause of dementia — a general term for a decline in memory, language, problem-solving, and other cognitive functions severe enough to interfere with daily life. Alzheimer’s is not a normal part of ageing; it is a distinct disease process caused by the abnormal accumulation of protein fragments in and around brain cells, progressively destroying neural networks that have taken decades to build.

At the cellular level, two hallmark abnormalities define Alzheimer’s pathology. First, amyloid-beta peptides — normally produced and cleared during wakefulness and sleep — misfold and aggregate into insoluble plaques that deposit between neurons, disrupting synaptic communication and triggering local inflammatory responses. Second, tau protein — which normally stabilises the microtubule scaffolding within neurons — becomes hyperphosphorylated, causing it to collapse and form neurofibrillary tangles that strangle neurons from within. Together, these changes drive the loss of acetylcholine-producing neurons in the nucleus basalis of Meynert, the degeneration of the hippocampus (the brain’s primary memory centre), and the eventual atrophy of the prefrontal and temporal cortices responsible for reasoning, language, and personality.

From a functional medicine perspective, Alzheimer’s is not simply a brain disease — it is a systemic failure with neurological consequences. Research by Dr. Dale Bredesen at the Buck Institute has identified at least three distinct metabolic subtypes: Type 1 (inflammatory), Type 2 (atrophic/hormonal), and Type 3 (toxic). This framework recognises that insulin resistance, sex hormone decline, chronic infections, environmental toxin burden, and mitochondrial impairment are not just risk factors but active, treatable drivers of amyloid and tau pathology. At Patients Medical, we use this systems-biology lens to investigate each patient’s individual constellation of drivers — and to intervene before irreversible neurodegeneration takes hold.

Alzheimer’s disease affects approximately 6.9 million Americans over the age of 65, with projections estimating nearly 13 million cases by 2050. Two-thirds of patients are women, likely due to the neuroprotective role of oestrogen and the accelerated neuronal vulnerability that accompanies menopause. The disease typically strikes after age 65 (late-onset), but early-onset Alzheimer’s — accounting for roughly 5–10% of cases — can begin as early as the 40s or 50s, often in individuals carrying the APOE4 genetic variant.

Hippocampus

The brain’s primary centre for consolidating new memories and spatial navigation. The hippocampus is the first region where Alzheimer’s pathology concentrates — shrinkage here is detectable by MRI years before significant cognitive symptoms appear, and explains why short-term memory failure is the earliest and most consistent symptom.

Prefrontal Cortex

The seat of executive function — planning, judgment, impulse control, and complex decision-making. As Alzheimer’s progresses from the hippocampus into the prefrontal cortex, patients lose the ability to manage finances, follow multi-step instructions, or navigate novel situations, despite sometimes retaining remote autobiographical memories.

Entorhinal Cortex & Default Mode Network

The entorhinal cortex serves as the gateway between the hippocampus and the rest of the cortex. It is among the earliest sites of tau pathology in Alzheimer’s disease, and disruption of its connections degrades the default mode network — the brain’s internal narrative and self-referential processing system — contributing to disorientation and loss of self-awareness in later stages.

Signs & Symptoms of Alzheimer's Disease

Alzheimer’s disease produces a wide and often overlapping spectrum of cognitive, neuropsychiatric, and physical symptoms because the disease progressively infiltrates multiple brain networks — the symptoms a patient experiences in a given year reflect precisely which neural circuits have been most affected by amyloid and tau pathology at that time.

Memory & Cognitive Symptoms

Episodic Memory Failure

Consistent inability to retain newly learned information — particularly recent conversations, appointments, or names — due to hippocampal degeneration and failure of long-term potentiation (synaptic memory encoding).

Word-Finding Difficulty (Aphasia)

Pausing mid-sentence, substituting incorrect words, or circling around a concept because temporal lobe degeneration disrupts the neural networks that connect semantic meaning to language output.

Impaired Executive Function

Difficulty managing finances, following complex recipes, or planning ahead — reflecting progressive prefrontal cortex involvement and loss of frontostriatal circuit integrity.

Disorientation to Time and Place

Losing track of the date, season, or year; becoming confused in familiar neighbourhoods — caused by entorhinal cortex and parietal lobe degeneration disrupting spatial and temporal orientation.

Visuospatial Deficits

Difficulty judging distances, reading, or recognising faces — reflecting parieto-occipital cortex involvement, particularly prominent in the posterior cortical atrophy variant of Alzheimer's.

Behavioural & Psychiatric Symptoms

Apathy and Social Withdrawal

Loss of motivation, interest in hobbies, and social engagement — the most common behavioural symptom, resulting from anterior cingulate cortex degeneration and disruption of dopaminergic reward circuits.

Personality and Mood Changes

Uncharacteristic suspicion, irritability, anxiety, or disinhibition — driven by amygdala and prefrontal degeneration, leading to loss of emotional regulation and impulse control.

Depression and Anxiety

Affects up to 50% of Alzheimer's patients, often predating diagnosis — linked to hippocampal serotonin system impairment and may also represent a response to awareness of cognitive decline.

Paranoia and Delusions

False beliefs — most commonly that possessions are being stolen — resulting from disrupted reality-monitoring circuits in the parietal and temporal lobes and cholinergic deficit.

Sundowning

Increased confusion, agitation, and disorientation in late afternoon and evening — reflecting pathological disruption of the suprachiasmatic nucleus and circadian rhythm dysregulation by amyloid pathology.

Sleep & Metabolic Symptoms

Progressive Sleep Disruption

Fragmented sleep architecture with reduced slow-wave and REM sleep — impairs the glymphatic clearance of amyloid-beta, creating a self-reinforcing cycle of neurodegeneration.

Appetite Changes and Weight Loss

Progressive anorexia and unexplained weight loss in later stages — reflecting hypothalamic dysfunction, olfactory impairment reducing food appeal, and loss of meal-routine sequencing.

Loss of Smell (Anosmia)

Often one of the earliest functional changes — the olfactory bulb is among the first sites of tau pathology, making anosmia a potential early biomarker years before cognitive symptoms.

Gait and Motor Changes

Shuffling gait, slowed movement, and increased fall risk emerge in later stages as Alzheimer's spreads to motor and parietal regions — often confused with comorbid Parkinson's disease.

Urinary Incontinence

Late-stage symptom reflecting degeneration of frontal lobe inhibitory control over the bladder — one of the functional milestones that typically signals advanced disease and increased care needs.

Functional & Daily-Life Symptoms

Repeated Questions and Statements

Asking the same question multiple times within minutes — a direct manifestation of hippocampal failure to encode and retain new episodic memories, often the most distressing symptom for families.

Misplacing Items in Illogical Places

Placing keys in the freezer or glasses in the bathroom cabinet — reflecting impaired spatial memory encoding and inability to retrace steps, distinct from normal occasional forgetfulness.

Losing the Ability to Drive Safely

Getting lost on familiar routes, misjudging distances, or forgetting traffic rules — visuospatial and executive deficits combine to make driving a significant safety concern in moderate-stage disease.

Difficulty with Financial Management

Susceptibility to financial exploitation, unpaid bills, or confusion over bank accounts — one of the earliest instrumental activities of daily living (IADL) to be compromised, often noticed by families before patients.

Loss of Interest in Personal Hygiene

Progressive neglect of bathing, grooming, and dental hygiene — driven by apathy, loss of self-awareness (anosognosia), and inability to sequence the steps of multi-stage self-care tasks.

The 4 Clinical Stages of Alzheimer's Disease

Staging Alzheimer’s disease is clinically essential because the appropriate interventions, care strategies, and realistic outcomes differ dramatically across the disease continuum. The National Institute on Aging and the Alzheimer’s Association (NIA-AA) framework identifies four broad stages — from a silent preclinical phase to late-stage dependency — and functional medicine’s most powerful opportunity lies in the earliest two stages, where modifiable biological drivers remain actionable.

01 Preclinical · Amyloid PET: Positive

Preclinical Alzheimer's Disease

The preclinical stage spans the 15–20 years before any cognitive symptoms appear. Amyloid-beta plaque accumulation and early tau seeding are detectable by PET scan and cerebrospinal fluid analysis, but the patient is functionally normal on standard cognitive testing. This is the highest-yield window for intervention: the brain’s compensatory reserve has not yet been depleted, and aggressive functional medicine treatment — addressing insulin resistance, neuroinflammation, hormonal decline, and toxin burden — can meaningfully alter the trajectory. Biomarker positivity without symptoms is identified in approximately 30% of cognitively normal adults over age 65.

02 MCI · MMSE: 24–30

Mild Cognitive Impairment (MCI) Due to Alzheimer's

MCI represents the symptomatic pre-dementia stage, in which subjective memory concerns are confirmed by objective testing — but functional independence is preserved. Patients notice word-finding difficulties, greater reliance on reminders, or difficulty multitasking. MCI is not inevitable progression: approximately 15–20% of MCI patients revert to normal cognition with intervention, particularly those in whom metabolic, hormonal, or inflammatory drivers are identified and corrected. The Bredesen ReCODE Protocol has documented reversal of MCI in multiple published case series. This stage typically lasts 2–4 years without intervention.

03 Mild–Moderate · MMSE: 10–24

Mild to Moderate Alzheimer's Disease

This is the stage at which most patients receive their formal Alzheimer’s diagnosis, typically 2–4 years after symptom onset. Patients need reminders for complex daily tasks, may repeat stories and questions frequently, and begin to require assistance with financial management and driving. Personality changes — apathy, irritability, anxiety — become more prominent as prefrontal involvement deepens. This stage is the longest in most patients’ trajectories (2–10 years) and represents the primary caregiving burden period. Functional medicine interventions at this stage aim to slow progression, preserve quality of life, reduce behavioural symptoms, and delay the transition to full dependency.

04 Severe · MMSE: <10

Severe (Late-Stage) Alzheimer's Disease

In the severe stage, the patient loses the ability to communicate verbally, recognise close family members, manage any activities of daily living, or ambulate independently. Swallowing difficulties (dysphagia), urinary and bowel incontinence, and susceptibility to pneumonia and pressure wounds characterise this phase. Full-time care is required. This stage typically lasts 1–3 years. Functional medicine care at this stage shifts to comfort-oriented neuroprotection — mitochondrial support, anti-inflammatory nutrition, and caregiver guidance — with the goal of preserving dignity and minimising distress rather than reversing disease.

Causes & Risk Factors for Alzheimer's Disease

Alzheimer’s disease is not caused by a single trigger — it results from the convergence of multiple interacting biological insults, each of which individually may be manageable but together overwhelm the brain’s capacity for repair and self-clearance. Understanding this multi-factorial aetiology is the foundation of functional medicine’s root-cause approach.

01

APOE4 Genetic Susceptibility

Carrying one copy of the APOE4 allele triples Alzheimer’s risk; two copies increases it 8–12-fold — APOE4 impairs amyloid clearance, promotes neuroinflammation, and reduces mitochondrial efficiency in neurons.

02

Insulin Resistance (Type 3 Diabetes)

Impaired insulin signalling in the brain reduces synaptic glucose uptake, disrupts amyloid-beta clearance via insulin-degrading enzyme, and promotes tau hyperphosphorylation — linking metabolic syndrome directly to neurodegeneration.

03

Chronic Neuroinflammation

Persistent microglial activation — triggered by infections, leaky gut, metabolic stress, or environmental toxins — sustains a low-grade inflammatory state that accelerates amyloid deposition and tau propagation throughout neural networks.

04

Mitochondrial Dysfunction

Neurons are extraordinarily metabolically demanding; mitochondrial energy failure — driven by oxidative stress, NAD+ depletion, and Complex I dysfunction — reduces the ATP available for amyloid clearance and synaptic maintenance.

05

Impaired Glymphatic Clearance

The glymphatic system — a brain-wide waste-clearance network activated during deep sleep — removes amyloid-beta and tau proteins; chronic sleep deprivation or poor sleep architecture allows these proteins to accumulate unopposed.

06

Oestrogen and Testosterone Decline

Both oestrogen and testosterone are directly neuroprotective — they regulate amyloid precursor protein processing, reduce neuroinflammation, and support synaptic density; the hormonal collapse of menopause is a key reason women account for two-thirds of Alzheimer’s cases.

07

Heavy Metal Neurotoxicity

Mercury (from amalgam fillings and fish), lead, and aluminium accumulate in brain tissue, promoting oxidative stress, inhibiting mitochondrial electron transport, and directly accelerating amyloid aggregation and tau phosphorylation.

08

Elevated Homocysteine

Plasma homocysteine above 11 μmol/L is associated with 2–3× increased Alzheimer’s risk — hyperhomocysteinaemia causes vascular endothelial damage, DNA strand breaks in neurons, and accelerated hippocampal atrophy detectable by MRI.

09

Gut Microbiome Dysbiosis

An imbalanced gut microbiome increases intestinal permeability (“leaky gut”), driving systemic lipopolysaccharide (LPS) translocation into the bloodstream, crossing a compromised blood-brain barrier, and activating neuroinflammatory cascades that accelerate amyloid pathology.

10

Thyroid Dysfunction

Both overt and subclinical hypothyroidism are associated with accelerated cognitive decline — thyroid hormones regulate synaptic plasticity, myelination, and neuronal metabolism, and even modestly elevated TSH predicts greater brain atrophy over time.

11

Chronic Infections (Viral, Bacterial, Fungal)

Herpes simplex virus-1 (HSV-1), Lyme borrelia, Porphyromonas gingivalis (oral bacteria), and Candida albicans have all been identified in post-mortem Alzheimer’s brain tissue — amyloid-beta may function as an antimicrobial peptide, trapping these pathogens but accelerating disease.

12

Cardiovascular and Cerebrovascular Disease

Hypertension, atrial fibrillation, and atherosclerosis compromise cerebral blood flow and oxygen delivery, promoting white matter damage, blood-brain barrier breakdown, and the development of mixed Alzheimer’s/vascular dementia pathology.

Alzheimer's Disease vs. Related Conditions

Alzheimer’s disease shares cognitive symptoms with several other neurological and metabolic conditions, and distinguishing between them is clinically critical because the treatment approach, prognosis, and reversibility differ markedly. The following comparison highlights key differentiators that inform both conventional and functional medicine evaluation.

Feature	Alzheimer’s Disease	Vascular Dementia	Lewy Body Dementia	Frontotemporal Dementia
Onset Pattern	Gradual, insidious	Stepwise, post-stroke	Gradual; fluctuating	Gradual; often <65 yrs
Hallmark Symptom	Episodic memory failure	Executive & processing speed deficits	Visual hallucinations + Parkinsonism	Personality & behaviour change
Key Biomarker	Amyloid PET / CSF Aβ42	MRI white matter lesions	DaTscan dopamine deficit	FDG-PET frontal hypometabolism
Best Diagnostic Test	Amyloid PET or CSF analysis	MRI brain + carotid ultrasound	DaTscan + polysomnography	Neuropsychological battery
Conventional Treatment	Cholinesterase inhibitors (donepezil)	Vascular risk factor control	Rivastigmine (avoid antipsychotics)	No approved therapy; supportive
Functional Medicine Overlap	Insulin resistance, inflammation, toxins	Cardiovascular risk reduction	Alpha-synuclein + mitochondrial support	Neuroinflammation and gut-brain axis

Important clinical note: Mixed dementia — the co-existence of Alzheimer’s pathology with vascular or Lewy body changes — affects an estimated 40–50% of dementia patients over age 80. Comprehensive functional medicine evaluation can identify and address the metabolic drivers common to all subtypes

How We Diagnose Alzheimer's Disease in NYC

01 APOE4 Genotyping & Genetic Panel

We begin with APOE genotyping to identify the E4 allele — the single largest genetic risk factor for late-onset Alzheimer’s, present in approximately 25% of the population but found in 50–65% of Alzheimer’s patients. APOE4 carriers require earlier and more aggressive intervention. We also assess MTHFR polymorphisms that impair homocysteine metabolism and B-vitamin utilisation. Available through our Genetic DNA Testing panel.

02 Comprehensive Metabolic & Insulin Resistance Panel

A fasting insulin level, HOMA-IR index, fasting glucose, HbA1c, and a full lipid panel with ApoB quantify the degree of insulin resistance and metabolic dysfunction — the “Type 3 diabetes” pathway that drives an estimated 50–80% of late-onset Alzheimer’s. Standard diabetes screening (HbA1c alone) misses the pre-diabetic insulin resistance that begins damaging neurons a decade before blood glucose rises. Assessed via our Metabolic Testing panel.

03 Neuroinflammation & Vascular Biomarkers

High-sensitivity C-reactive protein (hs-CRP), interleukin-6, fibrinogen, plasma homocysteine, and oxidised LDL collectively map the degree of systemic and vascular inflammation driving blood-brain barrier compromise and neurodegeneration. Homocysteine above 11 μmol/L independently predicts hippocampal atrophy and is correctable with methylated B vitamins. Our Oxidative Stress Testing further quantifies free radical burden on neurons.

04 Full Hormone Panel & Thyroid Assessment

We measure oestradiol, free testosterone, DHEA-S, progesterone, cortisol (4-point diurnal), free T3, free T4, reverse T3, TSH, and thyroid antibodies (TPO, TgAb). Each of these hormones plays a direct neuroprotective role — oestrogen reduces amyloid production, testosterone supports neuronal survival, and even subclinical hypothyroidism accelerates cognitive decline. Available through our Hormone Testing service.

05 Heavy Metal Provocation Testing & Organic Acids Panel

Urine heavy metal provocation testing (post-DMSA or DMPS chelation challenge) quantifies the body’s mercury, lead, aluminium, and arsenic burden — neurotoxins that accumulate over decades and directly inhibit mitochondrial function and amyloid clearance pathways. Organic acids testing (OAT) simultaneously assesses mitochondrial efficiency, B-vitamin status, neurotransmitter metabolites, and gut dysbiosis markers — providing a comprehensive view of the brain’s metabolic environment. See Heavy Metal Testing and Organic Acid Testing.

Does This Sound Like You?

Forgetting recent conversations or appointments regularly
Asking the same questions repeatedly without realising it
Word-finding difficulty that is getting worse over time
Getting lost in familiar environments or confused about dates
Family history of Alzheimer's or known APOE4 carrier status
Personality changes — increased anxiety, suspicion, or withdrawal
Sleep disruption, difficulty staying asleep, or vivid nightmares
Poor sense of smell or taste that has developed over recent years
Diagnosed with insulin resistance, metabolic syndrome, or prediabetes

Alzheimer's Disease Treatment at Patients Medical NYC

At Patients Medical, we treat Alzheimer’s disease and cognitive decline using a personalised, root-cause framework informed by each patient’s unique biomarker profile. Our approach is not about replacing conventional neurology — it is about addressing the upstream metabolic, hormonal, inflammatory, and toxic drivers that standard care does not assess. Every treatment plan is built on the results of comprehensive testing, regularly monitored, and adjusted based on measurable biomarker response and cognitive outcomes.

Bredesen ReCODE Protocol

The ReCODE (Reversal of Cognitive Decline) Protocol, developed by Dr. Dale Bredesen at the Buck Institute, is the most comprehensive evidence-based functional medicine programme for Alzheimer’s. It systematically addresses all identified subtypes (inflammatory, atrophic, toxic) through a personalised multi-intervention programme. Published case studies have documented objective cognitive reversal in MCI and early Alzheimer’s patients following this protocol.

ReCODE 2.0

Cognitive Tracking

MoCA Monitoring

Subtype Identification

NAD+ IV Infusion Therapy

NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme for mitochondrial energy production, DNA repair, and the activation of sirtuins — longevity proteins that regulate neuronal resilience. NAD+ levels decline by approximately 50% between ages 40 and 60. IV infusion bypasses gut absorption limitations to rapidly restore brain NAD+ levels, improving neuronal energy production and activating SIRT1-mediated neuroprotective pathways. Available through our NAD+ IV Therapy programme.

NAD+

NR / NMN oral support

Mitochondrial restoration

Targeted Nutraceutical Protocol

Based on each patient’s biomarker deficiencies, we prescribe pharmaceutical-grade nutraceuticals with clinical evidence for neuroprotection: omega-3 DHA (2–4g/day) to reduce neuroinflammation; phosphatidylserine (300mg/day) for synaptic membrane integrity; Lion’s Mane mushroom extract for nerve growth factor (NGF) stimulation; magnesium L-threonate to raise brain magnesium and synaptic density; curcumin-phosphatidylcholine complex for anti-amyloid and anti-inflammatory effects; and CoQ10 plus PQQ for mitochondrial biogenesis.

Omega-3 DHA

Phosphatidylserine

Lion's Mane

Magnesium L-Threonate

Curcumin Complex

CoQ10 + PQQ

Hormone Optimisation

Oestrogen, testosterone, progesterone, DHEA, and thyroid hormones are all directly neuroprotective — regulating amyloid precursor protein processing, synaptic density, neuronal survival, and inflammatory gene expression. When deficient, we prescribe bioidentical hormone replacement therapy (BHRT), carefully monitored by serum and salivary testing. In women at menopause, oestrogen replacement initiated within the critical 10-year window post-menopause has the strongest evidence for Alzheimer’s risk reduction. Available through our Bioidentical Hormone Replacement Therapy programme.

Bioidentical Oestradiol

Testosterone optimisation

Progesterone

DHEA-S

Thyroid support

Heavy Metal Chelation Therapy

For patients with confirmed elevated heavy metal burden — particularly mercury, lead, or aluminium — we implement medically supervised chelation therapy using DMSA (dimercaptosuccinic acid) orally or EDTA intravenously, depending on the metal profile. Chelation removes bound neurotoxic metals from tissue, reducing the oxidative and inflammatory load on neurons. This is preceded by nutritional support to ensure adequate antioxidant status and renal function monitoring throughout treatment. Available through our Chelation Therapy programme.

DMSA

EDTA IV

Pre-chelation nutrient priming

Post-chelation monitoring

Gut-Brain Axis Restoration

A disrupted gut microbiome drives systemic LPS (lipopolysaccharide) translocation, activating neuroinflammatory pathways that accelerate amyloid pathology. Our protocol uses comprehensive stool analysis (including microbiome sequencing), targeted probiotic therapy (Lactobacillus acidophilus NCFM, Bifidobacterium longum), prebiotic fibre prescription, intestinal permeability repair with L-glutamine and butyrate, and elimination of inflammatory dietary triggers. Normalising the gut-brain axis reduces systemic inflammation and supports neurotransmitter precursor availability. See our Gastrointestinal Testing.

Microbiome analysis

Probiotics

L-glutamine

Butyrate

Leaky gut repair

What to Expect: Treatment Timeline & Monitoring

Months 1–3	Comprehensive biomarker testing, protocol design, initial nutraceutical and dietary intervention, sleep optimisation. Baseline MoCA cognitive assessment documented.
Months 3–6	Hormonal and metabolic corrections initiated. NAD+ IV series commenced. Heavy metal chelation if indicated. Repeat inflammatory and metabolic biomarkers.
Months 6–12	Repeat cognitive assessment (MoCA). Biomarker response reviewed. Protocol adjusted based on response. Most patients report improved word-finding, sleep quality, and energy.
Ongoing (Annual)	Annual comprehensive biomarker review and cognitive assessment. Protocol maintenance or escalation. Caregiver support and care planning as appropriate.

Lifestyle Practices for Alzheimer's Disease Prevention & Recovery

Prioritise Slow-Wave Sleep for Glymphatic Clearance

Target 7–9 hours of sleep per night, with a consistent bedtime before 11 pm to maximise slow-wave sleep — the phase during which the glymphatic system removes amyloid-beta and tau. Practical protocol: take 0.3–1mg melatonin 60 minutes before bed, use blackout curtains, keep the bedroom at 65–68°F, and eliminate screens 90 minutes before sleep. If sleep apnoea is suspected, pursue polysomnography and CPAP therapy immediately, as untreated apnoea doubles Alzheimer's risk.

Perform Aerobic Exercise 4–5× Per Week

Aerobic exercise — particularly vigorous walking, cycling, or swimming at 70% maximum heart rate for 45 minutes — is the single most evidence-based lifestyle intervention for Alzheimer's prevention, directly increasing hippocampal volume, stimulating BDNF (brain-derived neurotrophic factor) synthesis, improving insulin sensitivity, and clearing amyloid via increased cerebral blood flow. Target 150 minutes of moderate-to-vigorous aerobic activity weekly plus twice-weekly resistance training to improve insulin signalling in muscle tissue.

Practice Daily Parasympathetic Activation

Chronic psychological stress chronically elevates cortisol, which directly accelerates hippocampal atrophy and synaptic loss. Daily parasympathetic activation via 10 minutes of 4-7-8 breathing (inhale 4 counts, hold 7, exhale 8), mindfulness meditation proven to increase grey matter in the prefrontal cortex, or yoga nidra body-scan practice measurably reduces cortisol, lowers hs-CRP, and improves sleep architecture. The MIND diet trial found that regular meditation as an adjunct to dietary intervention produced additive benefits for cognitive preservation.

Engage in Daily Cognitive Stimulation with Novelty

Cognitive reserve — the brain's resilience against neurodegeneration — is built by challenging, novel learning activities that activate prefrontal circuits and promote synaptic plasticity. The most evidence-supported activities combine novelty with social engagement: learning a new language (shown to delay Alzheimer's onset by 4–5 years on average), learning a musical instrument, social engagement through community activities, and complex strategy games. Passive activities (TV, word puzzles already mastered) do not build the same reserve.

Minimise Toxin Exposure and Support Detoxification

Reduce ongoing heavy metal accumulation by: replacing amalgam dental fillings with a biological dentist using SMART protocol; choosing low-mercury fish (sardines, salmon, mackerel) over high-mercury species (tuna, swordfish); filtering drinking water with NSF-certified filters removing lead and fluoride; using glass or stainless steel food storage; and reducing processed food packaging. Support hepatic phase 2 detoxification daily with cruciferous vegetables (sulforaphane activates Nrf2 and upregulates glutathione-S-transferase), sauna therapy (shown to reduce mercury levels in plasma), and adequate dietary fibre to prevent enterohepatic recirculation.

Cultivate Strong Social Engagement and Purpose

Social isolation is an independent risk factor for Alzheimer's disease — as impactful as physical inactivity or hypertension. Strong social networks stimulate bilateral prefrontal and temporal cortex activation, reduce cortisol and inflammatory cytokines, and protect against the depression that often precedes Alzheimer's. Practical strategies include: volunteering (provides purposeful social engagement and cognitive novelty simultaneously), regular face-to-face family contact, joining purpose-driven community groups, and mentoring — which produces particularly strong benefits for cognitive reserve.

Diet & Nutrition Guide for Alzheimer's Disease

Diet is one of the most powerful modifiable factors in Alzheimer’s disease prevention and management. The brain — comprising only 2% of body weight — consumes 20% of total energy and is exquisitely sensitive to glucose instability, oxidative stress, and inflammatory dietary signals. Both the MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) and the ketogenic diet have clinical trial evidence for slowing cognitive decline — the MIND diet reduced Alzheimer’s risk by 53% in the highest adherence group in its landmark 2015 trial.

The Single Most Important Dietary Change for Alzheimer's:

Eliminate all added sugars, refined carbohydrates, and ultra-processed foods from your diet. Chronic dietary glucose excess drives hyperinsulinaemia, which competitively inhibits insulin-degrading enzyme (IDE) — the primary enzyme responsible for breaking down amyloid-beta in the brain. Reversing insulin resistance through carbohydrate restriction is the most directly evidence-based dietary intervention for reducing amyloid accumulation. A low-glycaemic, unprocessed whole-food diet with a fasting window of 12–16 hours daily activates autophagy and optimises glymphatic function.

Eat — Foods That Support Brain Health

Wild-caught fatty fish (salmon, sardines, mackerel): Highest dietary source of omega-3 DHA — the primary structural lipid in neuronal membranes, shown to reduce amyloid production and neuroinflammation.
Dark leafy greens (kale, spinach, Swiss chard): Rich in folate, vitamin K1, and lutein — MIND diet's top-ranked food group for cognitive protection, reducing cognitive decline by the equivalent of 11 years in the Chicago Health study.
Blueberries and mixed berries: Anthocyanin polyphenols cross the blood-brain barrier, reduce neuroinflammation, and improve hippocampal signalling — the MIND diet recommends at least 2 servings per week.
Extra virgin olive oil (cold-pressed): Oleocanthal inhibits amyloid aggregation and tau phosphorylation; oleic acid supports myelin integrity; polyphenols reduce brain oxidative stress.
Walnuts and almonds: Walnuts are the only nut with significant ALA omega-3 content; their polyphenols reduce neuroinflammation; walnut consumption is inversely associated with cognitive decline in multiple cohort studies.
Cruciferous vegetables (broccoli, Brussels sprouts): Sulforaphane activates Nrf2 pathway, upregulating glutathione and thioredoxin — the brain's primary antioxidant defence enzymes that protect neurons from oxidative damage.
Pasture-raised eggs: The richest dietary source of choline — the precursor to acetylcholine, the neurotransmitter most depleted in Alzheimer's disease; also provides lutein, zeaxanthin, and omega-3s.
Fermented foods (kimchi, sauerkraut, kefir): Restore Lactobacillus and Bifidobacterium populations, reducing intestinal permeability and LPS translocation that drives neuroinflammatory cascades.
Green tea (EGCG): Epigallocatechin-3-gallate inhibits amyloid-beta aggregation, reduces tau phosphorylation, and activates autophagy — multiple clinical trials show inverse association between green tea consumption and dementia incidence.

Avoid — Foods That Accelerate Cognitive Decline

Sugar-sweetened beverages (soda, juice, sports drinks): Deliver concentrated fructose and glucose that spike insulin, suppress IDE, and directly drive the insulin resistance pathway to amyloid accumulation.
Ultra-processed foods (chips, crackers, fast food): High in advanced glycation end products (AGEs), seed oils rich in omega-6 linoleic acid, and refined carbohydrates — all of which promote neuroinflammation and oxidative stress.
Trans fats (partially hydrogenated oils): Trans fats are associated with a 75% increased risk of Alzheimer's disease in the highest consumption quintile — they incorporate into neuronal membranes, disrupting fluidity and signal transduction.
High-mercury fish (tuna, swordfish, king mackerel): Mercury directly inhibits Complex I of the mitochondrial electron transport chain, depletes glutathione, and promotes tau aggregation — choose low-mercury omega-3 sources instead.
Alcohol (particularly heavy consumption): Alcohol is directly neurotoxic to the hippocampus, disrupts sleep architecture and glymphatic clearance, depletes thiamine (B1 — essential for glucose metabolism in neurons), and promotes intestinal permeability.
Refined white flour products (bread, pasta, pastries): Rapidly spike blood glucose and insulin; provide minimal neuroprotective nutrients; promote the glycaemic variability that degrades cognitive performance acutely and insulin signalling chronically.
Processed red and cured meats (hot dogs, deli meats): Contain nitrites that generate nitrosamines in the gut, associated with insulin resistance in brain tissue and referred to as "Type 3 diabetes" inducers in NIH-funded research.
Margarine and vegetable shortening: Even "zero trans fat" reformulations contain high omega-6 linoleic acid from refined seed oils that compete with omega-3 DHA for incorporation into neuronal phospholipid membranes.

Related & Overlapping Conditions

Alzheimer’s disease rarely exists in isolation — it shares upstream biological drivers, overlapping biomarkers, and comorbid prevalence with a constellation of other conditions that functional medicine addresses in parallel.

Parkinson's Disease

Parkinson’s and Alzheimer’s share alpha-synuclein pathology, mitochondrial dysfunction, and neuroinflammatory drivers. Up to 80% of Parkinson’s patients develop cognitive impairment. The Lewy body dementia spectrum overlaps with both. Shared functional medicine interventions include NAD+ support, mitochondrial nutrients, and heavy metal chelation.

Memory Loss & Cognitive Decline

Age-associated memory impairment and subjective cognitive decline represent the earliest detectable signs of neurodegeneration, often years before meeting MCI criteria. Functional medicine evaluation at this stage offers the highest probability of reversing the trajectory through biomarker-guided intervention before structural brain changes become irreversible.

Diabetes & Metabolic Syndrome

Type 2 diabetes doubles Alzheimer’s risk and shares the insulin resistance pathway so directly that Alzheimer’s has been termed “Type 3 diabetes” in NIH-funded literature. The same interventions that correct insulin resistance — low-glycaemic diet, exercise, metformin, and berberine — also reduce Alzheimer’s risk, making metabolic optimisation an urgent priority for anyone with a family history.

Hashimoto's & Thyroid Disease

Thyroid hormones regulate neuronal metabolism, myelination, and synaptic plasticity. Hashimoto’s thyroiditis — the most common cause of hypothyroidism — is associated with accelerated cognitive decline and elevated dementia risk. Even subclinical hypothyroidism (elevated TSH with normal T4) predicts greater hippocampal atrophy over time, making thyroid optimisation a cornerstone of brain health.

Depression

Late-life depression is both a risk factor for and an early manifestation of Alzheimer’s disease — it may represent a neuroinflammatory prodrome rather than a distinct condition. The hippocampal volume loss seen in recurrent major depression mirrors early Alzheimer’s pathology. Treating depression aggressively and early with anti-inflammatory interventions may reduce Alzheimer’s risk.

Heavy Metals Toxicity

Mercury, lead, and aluminium accumulate preferentially in brain tissue over decades of low-level exposure, disrupting mitochondrial function, glutathione-dependent antioxidant defence, and amyloid clearance pathways. Heavy metal burden testing and chelation therapy are among the most powerful and under-recognised interventions for Alzheimer’s prevention in exposed populations.

When to See a Doctor About Alzheimer's Disease

If you or a family member are experiencing changes in memory, cognition, or behaviour, seeking a functional medicine evaluation sooner rather than later is the single most important action you can take. Alzheimer’s pathology begins accumulating 15–20 years before symptoms appear — by the time a diagnosis is made through standard channels, significant neuronal loss has often already occurred. The earlier we can identify and correct modifiable upstream drivers, the greater the opportunity to slow or reverse cognitive decline.

Seek a Functional Medicine Evaluation If:

You regularly forget recently learned information or important dates
Family or friends have noticed changes in your memory or judgement
You have a first-degree relative (parent or sibling) with Alzheimer's
Your homocysteine level has been found elevated on blood testing
You have a history of significant heavy metal exposure (occupational or dental)

You ask the same questions or repeat the same stories frequently
You have been diagnosed with APOE4 carrier status
You have been diagnosed with insulin resistance, prediabetes, or Type 2 diabetes
You have experienced menopause and are concerned about long-term brain health
You have been struggling with progressive sleep disruption for more than 6 months

🚨 Seek Emergency Medical Evaluation Immediately If: Sudden onset of severe confusion, profound disorientation, loss of speech, weakness on one side of the body, sudden severe headache, or vision changes — these may represent a stroke or acute neurological emergency that requires immediate ER evaluation and is NOT consistent with typical Alzheimer’s disease progression, which is always gradual. Sudden acute confusion (delirium) in a known Alzheimer’s patient may signal a serious infection, medication toxicity, or metabolic crisis requiring urgent medical attention.

What Our Patients Say About Alzheimer's & Cognitive Decline Treatment

Patient experiences are individual and may not reflect typical results. Names and identifying details have been changed to protect privacy. These accounts do not constitute medical claims regarding treatment outcomes.

"My mother was diagnosed with MCI at 68, and conventional neurology told us to 'watch and wait.' Dr. Gulati ran a panel of tests we had never heard of — APOE4 genotyping, fasting insulin, homocysteine, heavy metals — and found she had significant insulin resistance, elevated mercury from years of tuna consumption, and an MTHFR variant affecting B12. Within 8 months on the ReCODE protocol, her repeat MoCA improved from 24 to 27. We feel like we got our mother back."

"I'm 57, APOE4 positive, and watched my father lose everything to Alzheimer's in his 60s. I was terrified I was heading down the same path — I was forgetting words mid-sentence and felt cognitively foggy constantly. Patients Medical did a full functional workup and found my fasting insulin was at 18 (should be under 6), my oestrogen had crashed post-menopause, and my homocysteine was elevated. Six months of targeted treatment — low-carb diet, BHRT, methylated B-vitamins, and NAD+ IV — and the fog has cleared significantly. I finally feel proactive instead of helpless."

"My husband started forgetting conversations almost immediately after having them at age 71. His neurologist said the scans 'looked normal for his age' but to us it was obvious something was wrong. We came to Patients Medical for a second opinion. His organic acids test showed severe mitochondrial dysfunction, and his heavy metal test revealed significant lead accumulation. After 12 months of chelation, mitochondrial support supplements, and a ketogenic diet, his word recall has noticeably improved and he is sleeping through the night for the first time in years."

Explore Our Blog For More Insights

Frequently Asked Questions About Food Allergy

What is Alzheimer’s disease and how is it different from normal aging?

Alzheimer’s disease is a progressive, irreversible neurodegenerative disorder caused by the pathological accumulation of amyloid-beta plaques between neurons and hyperphosphorylated tau protein tangles within neurons, leading to widespread synaptic dysfunction and neuronal death. It is the most common form of dementia, accounting for 60–80% of all cases worldwide, and affects over 6.9 million Americans over age 65.

Normal ageing may cause mild slowing of recall or occasional forgetfulness — forgetting a name but remembering it later, or needing more time to learn new information. Alzheimer’s, by contrast, involves consistent forgetting of recently learned information, repeated questions, getting lost in familiar environments, and progressive loss of functional independence that cannot be attributed to normal ageing. The two are mechanistically distinct: normal ageing does not involve significant amyloid pathology or tau tangles, whereas Alzheimer’s represents a disease process that can begin accumulating pathology 15–20 years before symptoms appear.

Early identification of modifiable risk factors — insulin resistance, chronic inflammation, sleep apnoea, nutrient deficiencies, toxin burden — is the cornerstone of functional medicine’s approach to Alzheimer’s prevention and early intervention at Patients Medical.

What are the early warning signs of Alzheimer’s disease?

The earliest warning signs of Alzheimer’s disease typically emerge years before a formal diagnosis and are often dismissed as normal ageing or stress. Key early signs include: consistent difficulty remembering recently learned information (particularly new names, appointments, or conversations); asking the same questions repeatedly within a short time frame; increasing reliance on memory aids for tasks previously managed independently; and noticeable difficulty with complex planning, such as following a familiar recipe or managing finances.

Additional early signs include: getting confused about dates, seasons, or the passage of time; misplacing items in illogical locations and losing the ability to retrace steps; changes in mood, personality, or social engagement — becoming withdrawn, suspicious, anxious, or uncharacteristically passive; and word-finding difficulties that go beyond the occasional tip-of-the-tongue experience.

From a functional medicine perspective, early cognitive changes may be accompanied by metabolic signals: elevated fasting insulin, rising homocysteine, declining DHEA-S, or worsening sleep quality — all of which are measurable and addressable years before neurodegeneration becomes irreversible. If you recognise these signs in yourself or a loved one, a functional medicine evaluation with comprehensive biomarker testing is the most proactive step you can take.

How long does Alzheimer’s disease progression take?

The progression of Alzheimer’s disease varies considerably between individuals, but the average duration from first symptom onset to end-stage disease is 8 to 12 years, with a range of 3 to 20 years. The preclinical phase — during which amyloid and tau pathology accumulates silently — can span 15–20 years before any symptoms are detectable.

The mild cognitive impairment (MCI) stage typically lasts 2–4 years, though not all MCI cases progress to Alzheimer’s — particularly with aggressive lifestyle intervention. The mild Alzheimer’s stage, when diagnosis is usually made, typically lasts 2–4 years. Moderate Alzheimer’s is the longest stage for most patients, lasting 2–10 years, characterised by increasing daily care needs. Severe or late-stage Alzheimer’s typically lasts 1–3 years.

Functional medicine interventions — targeting insulin resistance, inflammation, mitochondrial dysfunction, and toxin burden — have shown promise in slowing progression and, in some cases via the Bredesen Protocol, reversing early cognitive decline. Monitoring response with repeat cognitive assessments (MoCA) and biomarker panels every 6–12 months is standard practice at Patients Medical.

What tests diagnose Alzheimer’s disease at Patients Medical?

Conventional diagnosis of Alzheimer’s disease relies on clinical neuropsychological testing (such as the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE)), brain imaging (MRI or PET scan for amyloid and tau), and in some centres, cerebrospinal fluid (CSF) analysis for amyloid-beta and phospho-tau ratios. A functional medicine evaluation at Patients Medical goes significantly further by identifying the upstream metabolic drivers of cognitive decline.

Our Alzheimer’s workup includes: APOE4 genotyping to assess genetic susceptibility; comprehensive metabolic panel with fasting insulin and HOMA-IR to identify insulin resistance; plasma homocysteine and methylation panel (MTHFR, B12, folate) to assess vascular and neurological risk; high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 to quantify neuroinflammation; full thyroid panel including free T3, free T4, reverse T3, and thyroid antibodies; sex hormone panel (oestradiol, testosterone, DHEA-S, progesterone) as hormones are directly neuroprotective; heavy metal urine provocation testing for mercury, lead, and aluminium; and organic acids testing for mitochondrial function and neurotransmitter metabolites.

This comprehensive picture allows us to build a personalised intervention plan targeting each patient’s specific constellation of drivers — rather than applying a generic protocol regardless of root cause.

What is the difference between Alzheimer’s disease and vascular dementia?

Alzheimer’s disease and vascular dementia are the two most common forms of dementia, and they frequently co-exist — a condition called mixed dementia affecting an estimated 40–50% of dementia patients over age 80. Alzheimer’s disease is characterised by the gradual, progressive accumulation of amyloid-beta plaques and tau neurofibrillary tangles, causing a slow, continuous decline beginning with memory impairment.

Vascular dementia, by contrast, is caused by reduced blood flow to the brain — typically from strokes (large or small vessel), atherosclerosis, or chronic hypertension — producing a more stepwise, unpredictable deterioration pattern often with prominent executive function deficits and slowed processing speed rather than early memory loss. Key distinguishing features: Alzheimer’s typically begins with episodic memory failure; vascular dementia often begins with attention, planning, and processing speed deficits. Alzheimer’s is associated with APOE4 genotype and amyloid PET positivity; vascular dementia with white matter hyperintensities on MRI and cardiovascular risk markers.

Functional medicine addresses both through overlapping interventions: optimising blood pressure and vascular inflammation, correcting insulin resistance, and supporting mitochondrial energy production in neurons. The presence of mixed pathology — which is common — makes comprehensive biomarker evaluation even more important.

How does Alzheimer’s disease affect sleep, and why does sleep matter for brain health?

Sleep and Alzheimer’s disease share a deeply bidirectional relationship. During slow-wave (deep) sleep, the brain’s glymphatic system activates, flushing amyloid-beta and tau proteins from interstitial fluid into the bloodstream for clearance. Even one night of poor sleep measurably increases amyloid-beta burden in the brain, as demonstrated by landmark NIH research using PET imaging.

People with Alzheimer’s consistently show disrupted slow-wave sleep, reduced REM duration, increased nighttime awakening, and the characteristic ‘sundowning’ phenomenon — increased confusion, agitation, and disorientation in late afternoon and evening — thought to result from disturbance of the suprachiasmatic nucleus (the circadian pacemaker) by amyloid pathology. Chronically disrupted sleep creates a vicious cycle: poor sleep → amyloid accumulation → worse sleep → further neurodegeneration.

At Patients Medical, we assess sleep quality using salivary cortisol rhythms, melatonin testing, and home sleep studies where indicated. Targeted interventions — magnesium glycinate, low-dose melatonin, progesterone optimisation in women, treatment of underlying sleep apnoea, and morning bright light therapy for circadian entrainment — form a critical part of our Alzheimer’s neuroprotection protocol. Treating sleep apnoea alone has been shown in multiple studies to significantly slow the rate of cognitive decline.

What supplements and treatments support Alzheimer’s prevention and management?

A growing body of clinical and preclinical research supports several nutraceuticals as part of a comprehensive functional medicine strategy for Alzheimer’s disease. The most evidence-based include: Omega-3 DHA (docosahexaenoic acid) at 2–4g per day — the primary structural fat in neuronal membranes, shown to reduce amyloid production and neuroinflammation; phosphatidylserine (300mg/day) — a phospholipid critical for synaptic membrane integrity, with clinical trials demonstrating improved memory and cognition; and Lion’s Mane mushroom (Hericium erinaceus) — stimulates Nerve Growth Factor (NGF) production, promoting neuronal repair and synaptic plasticity.

Additional evidence-supported nutraceuticals include: magnesium L-threonate — the only form of magnesium demonstrated to cross the blood-brain barrier and raise brain magnesium levels, improving synaptic density; citicoline (CDP-choline) — supports acetylcholine synthesis and membrane repair; CoQ10 and PQQ (pyrroloquinoline quinone) — mitochondrial support nutrients that reduce oxidative stress in neurons; methylated B-vitamins (B12 as methylcobalamin, B6, methylfolate) — essential for homocysteine methylation and myelin preservation; and NAD+ precursors (nicotinamide riboside or NMN) — restore mitochondrial NAD+ levels that decline with age and Alzheimer’s progression.

All supplementation at Patients Medical is guided by individual biomarker testing and is never a one-size-fits-all protocol. Dosing, form, and combination are personalised based on each patient’s specific deficiencies and genetic variations.

Ready to Understand Your Alzheimer's Risk?

At Patients Medical, we go beyond conventional neurology to investigate the metabolic, hormonal, inflammatory, and toxic drivers that standard care misses — giving you a complete picture and a personalised roadmap to protect your brain.

(212) 794-8800 · 800 Second Avenue, Suite 900, New York, NY 10017

Begin Your Journey with Patients Medical

Patients Medical specializes in gently helping the patient identify the root cause of their medical issues and then assist them to recover from their problems to help them move forward to good health.

Request your consultation today!

To schedule an in person on Tele-medicine appointment, please call our office at (212) 794-8800 or email us at info@PatientsMedical.com We look forward to hearing from you

Our medical center in New York City.

Patients Medical PC
1148 Fifth Avenue, Suite 1B New York, NY 10128

Make an Appointment

TreatmentsTesting

Please leave this field empty.